TABLE 2

Hazard ratios^# for relationship between quantitative immunostaining and death in 43 interstitial lung disease patients, 1999–2009

Biomarker	Method	Group (patients n)	Hazard ratio (95% CI)	p-value for trend
αvβ6	Semiquantitative	Group 1: 0–30% (3)	1	0.0019
		Group 2: 30–≤50% (14)	0.71 (0.134–3.80)
		Group 3: 50–≤70% (12)	0.76 (0.15–3.88)
		Group 4: >70% (14)	4.19 (0.87–20.23)
	Automated	Group 1: low expression (15)	1	0.25
		Group 2: medium expression (14)	0.98 (0.32–3.06)
		Group 3: high expression (14)	2.07 (0.75–5.7)
αSMA	Semiquantitative	Group 1: 0–30% (2)	1	0.49
		Group 2: 30–≤50% (8)	0.99 (0.10–9.74)
		Group 3: 50–≤70% (12)	4.54 (0.49–41.93)
		Group 4: >70% (21)	1.77 (0.22–14.01)
	Automated	Group 1: low expression (15)	1	0.72
		Group 2: medium expression (14)	1.23 (0.41–3.73)
		Group 3: high expression (14)	1.54 (0.52–4.54)
HGF	Semiquantitative	Group 1: 0–30% (1)	1	0.94
		Group 2: 30–<50% (12)	0.63 (0.074–5.30)
		Group 3: 50–<70% (13)	0.60 (0.070–5.09)
		Group 4: >70% (17)	0.71 (0.087–5.75)
	Automated	Group 1: low expression (15)	1	0.41
		Group 2: medium expression (14)	1.70 (0.65–4.48)
		Group 3: high expression (14)	0.84 (0.28–2.52)
SP-C^¶	Semiquantitative	Group 1: 0–30% (12)	1	0.99
		Group 2: 30–≤50% (14)	1.17 (0.37–3.70)
		Group 3: 50–≤70% (9)	1.25 (0.32–4.78)
		Group 4: >70% (8)	1 (0.30–3.28)
TenC⁺	Semiquantitative		1.16 (0.36–1.97)	0.58
	Automated	Group 1: low expression (15)	1	0.57
		Group 2: medium expression (14)	1.62 (0.55–4.83)
		Group 3: high pressure (14)	1.76 (0.55–5.62)

αSMA: α-smooth muscle actin; HGF: hepatocyte growth factor; SP-C: surfactant protein C; TenC: tenascin-C. ^#: adjusted for age and sex; ^¶: automated analysis was not possible for SP-C due to a high degree of false-positive staining; ⁺: only the trend for the semiquantitative method is shown, as there were no deaths in group 4.